The CHALLENGE trial, led by the Canadian Cancer Trials Group and enrolling patients from 2009 across six countries, is the strongest evidence yet that structured exercise coaching meaningfully improves survival after colon cancer. Of 889 stage 2 or 3 patients who had completed surgery and chemotherapy, those randomized to three years of physical activity consulting were significantly less likely to see their cancer return, develop a new cancer, or die. The exercise group logged 93 adverse events against 131 in the control arm. At eight years, roughly 90 of every 100 people in the exercise group were alive, versus 83 of 100 in the education-only group — a 7-percentage-point survival gap. The intervention was modest by gym-culture standards: 45 to 60 minutes of brisk walking, three to four times a week, tailored to the individual. The coaching aimed not at athletic performance but at habit formation — making patients independent exercisers in their own environments. The trial's design constrains its reach. Participants had to pass a fitness test before enrolling, which means the population skewed younger, healthier, and more motivated than a typical oncology waiting room. Tormod Skogstad Nilsen, a Norwegian cancer exercise researcher, flagged this directly: many patients decline exercise trials because they feel too unwell or simply don't want to exercise. The finding is real but bounded. Separately, a 2025 UK study of 85,000 adults wearing wrist trackers found those who moved most had 26% lower risk across 13 cancer types. Even light activity — household chores — was linked to lower risk after adjusting for lifestyle, weight, and other conditions. This echoes a 2016 analysis of 1.44 million adults in the US and Europe. The observational evidence is consistent and large-scale, though it cannot prove causation the way CHALLENGE can for post-diagnosis outcomes. The delivery gap is stark. A 2024 survey of 549 cancer patients found only 1 in 10 had been referred to an exercise service, yet nearly 3 in 4 believed their oncologist should raise the subject. Anna Campbell of Edinburgh Napier University sees the fix in pathway design: surgeons, oncologists, and community fitness instructors all connected, with one clinical champion linking the chain. From January 2027, US breast cancer centers will be required to screen patients' physical function and recommend exercise or physical therapy. This is the regulatory signal that the evidence base has crossed a threshold. But Campbell expects the CHALLENGE model's three-year coaching to be cut back in real-world implementation. The alternatives — apps, live online group sessions — can work if staffed by trained professionals and designed to reach rural, low-income, and advanced-cancer patients. The structural question is whether health systems will fund preventive coaching or continue to spend overwhelmingly on treatment. The CHALLENGE data makes the case that a low-cost behavioral intervention — walking, not drugs — materially shifts survival curves. The bottleneck is not evidence but infrastructure, workforce, and the political will to pay for care that doesn't come in a vial.
